Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia. Issue 1 (January 2020)

• Record Type: Journal Article
• Authors: Jeyaraman, Preethi; Naithani, Rahul
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 1(2020)
• Publication Date: 2020-01
• Subjects: Imatinib cessation -- pediatric CML -- tyrosine kinase inhibitors; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001624
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Chronic myeloid leukemia (CML) has different disease biology with a more aggressive clinical course in children. Achieving treatment-free remission is the ideal goal for the pediatric CML population to avoid long-term toxicities of tyrosine kinase inhibitors. Here, we present our experience of stopping Imatinib in a pediatric patient of CML who had excessive weight gain with Imatinib. He is currently maintaining treatment-free remission for 15 months after stopping therapy at the time of last follow-up. The patient also had normalization of body mass index with the stopping of Imatinib.